An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin (Dalteparin Sodium) In Patients Undergoing Major Orthopedic Surgery.

Trial Profile

An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin (Dalteparin Sodium) In Patients Undergoing Major Orthopedic Surgery.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2012

At a glance

  • Drugs Dalteparin sodium (Primary)
  • Indications Thrombosis
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Feb 2012 Actual patient number changed from 494 to 503 as reported by ClinicalTrials.gov.
    • 15 Apr 2011 Actual patient numbers reported as 494 by the ClinicalTrials.gov record
    • 15 Apr 2011 Status changed from not yet recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top